215 related articles for article (PubMed ID: 22104048)
1. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
2. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
3. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
4. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
5. [CTLA4-Ig].
Miyasaka N
Nihon Rinsho; 2005 May; 63 Suppl 5():751-5. PubMed ID: 15954440
[No Abstract] [Full Text] [Related]
6. [Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
Yasuoka Y; Goto A; Seriu T
Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):87-94. PubMed ID: 21321458
[No Abstract] [Full Text] [Related]
7. [CTLA4-Ig (abatacept)].
Harigai M
Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
[TBL] [Abstract][Full Text] [Related]
8. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
9. [Abatacept in the treatment of active rheumatoid arthritis].
Nielsen H; Hansen A
Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034
[TBL] [Abstract][Full Text] [Related]
10. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
[No Abstract] [Full Text] [Related]
11. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.
Bonelli M; Ferner E; Göschl L; Blüml S; Hladik A; Karonitsch T; Kiener HP; Byrne R; Niederreiter B; Steiner CW; Rath E; Bergmann M; Smolen JS; Scheinecker C
Arthritis Rheum; 2013 Mar; 65(3):599-607. PubMed ID: 23203906
[TBL] [Abstract][Full Text] [Related]
12. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
13. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
14. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
15. T-cell regulation by CD28 and CTLA-4.
Alegre ML; Frauwirth KA; Thompson CB
Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
[TBL] [Abstract][Full Text] [Related]
16. Critical role of costimulation in the activation of naive antigen-specific TCR transgenic CD8+ T cells in vitro.
Chai JG; Vendetti S; Bartok I; Schoendorf D; Takacs K; Elliott J; Lechler R; Dyson J
J Immunol; 1999 Aug; 163(3):1298-305. PubMed ID: 10415027
[TBL] [Abstract][Full Text] [Related]
17. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH; Durez P; Hallegua D; Aranda R; Becker JC; Nuamah I; Vratsanos G; Zhou Y; Moreland LW
J Rheumatol; 2006 Nov; 33(11):2162-6. PubMed ID: 17014006
[TBL] [Abstract][Full Text] [Related]
18. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.
Teng GG; Turkiewicz AM; Moreland LW
Expert Opin Biol Ther; 2005 Sep; 5(9):1245-54. PubMed ID: 16120053
[TBL] [Abstract][Full Text] [Related]
19. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
[TBL] [Abstract][Full Text] [Related]
20. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis.
Choy EH
Clin Exp Rheumatol; 2009; 27(3):510-8. PubMed ID: 19604448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
